PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics

[1]  L. Olson,et al.  Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation , 2017, Pharmacogenetics and genomics.

[2]  M. Tsai,et al.  Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[3]  Julia M. Barbarino,et al.  PharmGKB summary: voriconazole pathway, pharmacokinetics , 2017, Pharmacogenetics and genomics.

[4]  Li Zhu,et al.  CYP2C19 Genotype–Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir‐Boosted Atazanavir in Healthy Subjects , 2017, Journal of clinical pharmacology.

[5]  R. Shafer,et al.  2017 Update of the Drug Resistance Mutations in HIV-1. , 2016, Topics in antiviral medicine.

[6]  C. Aquilante,et al.  Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). , 2016, The Journal of antimicrobial chemotherapy.

[7]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing , 2016, Clinical pharmacology and therapeutics.

[8]  B. Weinberger,et al.  Inherited disorders of bilirubin clearance , 2016, Pediatric Research.

[9]  G. di Perri,et al.  Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). , 2015, The Journal of antimicrobial chemotherapy.

[10]  M. J. Kasten,et al.  Management of HIV/AIDS in older patients–drug/drug interactions and adherence to antiretroviral therapy , 2015, HIV/AIDS.

[11]  Hsiu‐Po Wang,et al.  Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy , 2015, PloS one.

[12]  J. Currier,et al.  A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness , 2015, AIDS.

[13]  L. Olson,et al.  Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia , 2015, Open forum infectious diseases.

[14]  U. Lalloo,et al.  Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial , 2015, HIV clinical trials.

[15]  K. Ruxrungtham,et al.  Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. , 2015, Journal of acquired immune deficiency syndromes.

[16]  D. Hawkins,et al.  Atazanavir Exposure is Effective during Pregnancy Regardless of Tenofovir Use , 2015, Antiviral therapy.

[17]  H. Yazaki,et al.  Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. , 2014, The Journal of antimicrobial chemotherapy.

[18]  P. Sax,et al.  Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. , 2014, The Journal of antimicrobial chemotherapy.

[19]  G. di Perri,et al.  Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. , 2014, The Journal of antimicrobial chemotherapy.

[20]  Jennifer A. Johnson,et al.  Beginning antiretroviral therapy for patients with HIV. , 2014, Infectious disease clinics of North America.

[21]  A. Pau,et al.  Antiretroviral therapy: current drugs. , 2014, Infectious disease clinics of North America.

[22]  F. D. De Rosa,et al.  Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. , 2014, Pharmacogenomics.

[23]  B. Conway,et al.  A meta‐analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir‐boosted protease inhibitor maintenance therapy in HIV‐infected adults with established virological suppression after induction , 2014, HIV medicine.

[24]  S. Oka,et al.  Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. , 2014, The Journal of antimicrobial chemotherapy.

[25]  M. Ritchie,et al.  Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202 , 2014, Pharmacogenetics and genomics.

[26]  S. Walmsley,et al.  In Vitro and In Situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents , 2014, Pharmaceutical Research.

[27]  Julia M. Barbarino,et al.  PharmGKB summary: very important pharmacogene information for UGT1A1 , 2014, Pharmacogenetics and genomics.

[28]  D. Katzenstein,et al.  Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Monica Kumar,et al.  Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens , 2014, Journal of the International AIDS Society.

[30]  S. Oka,et al.  Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients , 2013, PloS one.

[31]  S. Oka,et al.  Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors? , 2013, PloS one.

[32]  E. Plise,et al.  Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. , 2013, Molecular pharmaceutics.

[33]  S. Harbeson,et al.  Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry. , 2013, Journal of mass spectrometry : JMS.

[34]  D. H. Watts,et al.  Pharmacokinetics of an Increased Atazanavir Dose With and Without Tenofovir During the Third Trimester of Pregnancy , 2013, Journal of acquired immune deficiency syndromes.

[35]  P. Sax,et al.  Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. , 2013, The Journal of infectious diseases.

[36]  S. Khoo,et al.  Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies , 2013, Journal of acquired immune deficiency syndromes.

[37]  E. Clercq.  The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). , 2013 .

[38]  S. Walmsley,et al.  Role of Drug Efflux and Uptake Transporters in Atazanavir Intestinal Permeability and Drug-Drug Interactions , 2012, Pharmaceutical Research.

[39]  P. Tattevin,et al.  Complicated atazanavir-associated cholelithiasis: a report of 14 cases. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  S. Oka,et al.  High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  C. Aquilante,et al.  A population pharmacokinetic-pharmacogenetic analysis of atazanavir. , 2012, AIDS research and human retroviruses.

[42]  E. Clementi,et al.  Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. , 2012, The Journal of antimicrobial chemotherapy.

[43]  Ulf Norinder,et al.  Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.

[44]  C. Torti,et al.  Unboosted Atazanavir for Treatment of HIV Infection , 2012, Drugs.

[45]  S. Urien,et al.  Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents. , 2011, British journal of clinical pharmacology.

[46]  E. Acosta,et al.  Steady-State Pharmacokinetics of Tenofovir-Based Regimens in HIV-Infected Pediatric Patients , 2011, Antimicrobial Agents and Chemotherapy.

[47]  Chengcheng Hu,et al.  Atazanavir Pharmacokinetics With and Without Tenofovir During Pregnancy , 2011, Journal of acquired immune deficiency syndromes.

[48]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[49]  Mark George Thomas,et al.  Prevalence of Clinically Relevant UGT1A Alleles and Haplotypes in African Populations , 2011, Annals of human genetics.

[50]  M. Wempe,et al.  Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment , 2011, Drug Metabolism and Disposition.

[51]  Jie Lu,et al.  CYP3A-Mediated Generation of Aldehyde and Hydrazine in Atazanavir Metabolism , 2011, Drug Metabolism and Disposition.

[52]  Matthias Cavassini,et al.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. , 2011, The Journal of infectious diseases.

[53]  V. Soriano,et al.  Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance , 2010, Antimicrobial Agents and Chemotherapy.

[54]  W. Bierman,et al.  Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. , 2010, The Journal of antimicrobial chemotherapy.

[55]  P. G. Choe,et al.  Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  Zhiwei Ye,et al.  Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1 , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[57]  S. Khoo,et al.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms , 2010, Pharmacogenetics and genomics.

[58]  B. Gazzard,et al.  Factors influencing lopinavir and atazanavir plasma concentration. , 2010, The Journal of antimicrobial chemotherapy.

[59]  A. Calcagno,et al.  Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. , 2009, Journal of acquired immune deficiency syndromes.

[60]  C. Aquilante,et al.  Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. , 2009, The Journal of antimicrobial chemotherapy.

[61]  H. Rosing,et al.  Identification and Profiling of Circulating Metabolites of Atazanavir, a HIV Protease Inhibitor , 2009, Drug Metabolism and Disposition.

[62]  S. Khoo,et al.  Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  J. Molina,et al.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study , 2008, The Lancet.

[64]  D. Harris,et al.  Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus Infection , 2007, Antimicrobial Agents and Chemotherapy.

[65]  S. Staszewski,et al.  Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults , 2007, European Journal of Clinical Pharmacology.

[66]  Melissa M. Truffa,et al.  Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System , 2007, AIDS.

[67]  M. Fischl,et al.  Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. , 2007, Pharmacogenomics.

[68]  V. Soriano,et al.  Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia , 2007, AIDS.

[69]  M. Manns,et al.  Gilbert's disease and atazanavir: From phenotype to UDP‐glucuronosyltransferase haplotype , 2006, Hepatology.

[70]  R. Shafer.  Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.

[71]  V. Soriano,et al.  Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  Amalio Telenti,et al.  Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. , 2005, The Journal of infectious diseases.

[73]  C. Goujard,et al.  Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir , 2005, Clinical pharmacokinetics.

[74]  D. Margolis,et al.  Atazanavir for the Treatment of Human Immunodeficiency Virus Infection , 2004, Pharmacotherapy.